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Abstract
Understanding how patient-reported quality of life (QoL) and socioeconomic sta-
tus (SES) relate to survival of acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS) may improve prognostic information sharing. This study explores
associations among QoL, SES, and survival through administration of the Euro-QoL
5-Dimension, 3-level and Functional Assessment of Cancer Therapy-Leukemia and
financial impact questionnaires to 138 adult participantswith newly diagnosedAMLor
MDS in a longitudinal, pan-Canadian study. Cox regression and lasso variable selection
models were used to explore associations amongQoL, SES, and established predictors
of survival. Secondary outcomeswere changes in QoL, performance of theQoL instru-
ments, and lost income. We found that higher QoL and SES were positively associated
with survival. The Lasso model selected the visual analog scale of the EQ-5D-3L as the
most important predictor among all other variables (P = .03; 92% selection). Patients
with AML report improved QoL after treatment, despite higher mean out-of-pocket
expenditures comparedwithMDS (up to $599CDN/month for AML vs $239 forMDS;
P = .05), greater loss of productivity-related income (reaching $1786/month for AML
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vs $709 for MDS; P < .05), and greater caregiver effects (65% vs 35% caregiver pro-
ductivity losses for AML vs MDS; P < .05). Our results suggest that including patient-
reported QoL and socioeconomic indicators can improve the accuracy of survival
models.
1 INTRODUCTION
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
are malignancies of myeloid lineage, affecting around 10 individuals
per 100 000, every year. Incidence rates nearly triple for those 70 and
older and survival outcomes are poorer with increased age [1,2]. Deci-
sions to offer curative treatments with allogeneic stem cell transplants
(alloSCT) are guided by risk factors that are a function of increased
age and/or disease progression [3,4]. Most other treatment options
are, generally, noncurative in intent. TheNational ComprehensiveCan-
cer Network (NCCN) guidelines consider cytogenetic abnormalities,
leukemogenic mutations, co-morbidities, and geriatric conditions with
established prognostic value [5-8]. Relatively less is known about the
contribution of other risk factors that are independent of age or dis-
ease progression, such as quality of life (QoL) and socioeconomic sta-
tus (SES). If other risk factors independently contribute to survival
outcomes, then the accuracy of prognostic risk models may be
improved through standardized data collection and incorporation into
real-world models.
There is a growing literature that suggests patient-reported out-
comes, such as QoL, may improve the accuracy of risk models used
to predict survival outcomes. Incorporating patient-reported fatigue,
for example, into the International Prognostic Scoring System forMDS
(IPSS) has improved survival prediction [9]. The prognostic value of
patient-reported health status for AML is less clear. One study in Italy
reports a positive association between patient-reported QoL scores
and survival of elderly adults with AML [10], whereas in Canada, the
same association has not beenmade [11,12].
Missing or invisible prognostic data—such as patient-reported
QoL—may be a source of error in evaluating chances of successful
treatment if it is impactful. There is reason to believe that QoL both
impacts survival and is a measurable outcome for treatment. Long-
term AML survivors have reported poorer QoL compared to age-
matched members of the population without exposure to the disease
or treatment [13]. The ability to evaluate new treatments also requires
QoL data to estimate cost-effectiveness [14]. Because economic mod-
els depend on data from patients, and these QoL data do not exist,
the ability to evaluate new treatments would be improved with more
knowledge in this area.
Socioeconomic indicators are another unexplored and potentially
impactfulmissing data. Studies in the Swedish population, have shown
that elderly patients with geographic access to intensive treatment for
AML live longer than those without [15]. If risks such as geographic
access are found to be impactful on survival, then policy to address
equitable access can be developed. If inequitable access to treatment
remains an issue, however, the resulting survival data that are gener-
ated will inevitably suffer from selection bias. Black people with AML
in the United States, for example, have less access to curative treat-
ment for AML, inadequate alloSCT donor availability, and poorer out-
comes after treatment—therefore, they are less likely to be able to con-
tribute long-term survival data to predictive models and their health
outcomes remain underrepresented [16]. Access to follow-up care is
further restricted by tiers of insurance coverage, thus outcomes com-
monly overreport results for patients who are privately insured [17].
Knowledge on the contribution that patient-reported outcomes
and/or SES has on survival and the resulting datasets generated could
lead to improved modeling and better communication between clini-
cians and to patients and their families. In this study, we aim to explore
the potential of these data to improve the accuracy of survival model-
ing and our understanding of how QoL and socioeconomic indicators
change following treatment for AML and MDS. The study was part of
the Terry Fox Research Institute’s Prognostic Risk study for AML and
MDS (NCT01685619), undertaken at six study centers across Canada.
2 MATERIALS AND METHODS
2.1 Patients
Adults (age > 19) with a suspected diagnosis of AML or MDS were
invited to join the observational, prognostic risk study, at six major
cancer centers across Canada. The study was designed to collect bio-
logical, clinical, and patient-reported outcomes data from newly diag-
nosed patients with AML or MDS. The overall study objective was
to explore prognostic indicators related to remission and survival
including genomic and molecular indicators under investigation by the
laboratory-based investigators, and clinical outcomes such as survival,
QoL, health status, and personal financial impacts for patients with
AML or MDS, over 24 months of follow-up. Patients were consid-
ered for enrollment in part two of the study if a diagnosis of AML
or MDS was confirmed from a bone marrow biopsy and patients re-
consented to the study. Demographic characteristics were obtained
at baseline and changes to QoL and personal financial impacts were
assessed over five follow-up time points: baseline (T0), 3 months
(T1), 6 months (T2), 12 months (T3), 18 months (T4), and 24 months
(T5). Recruitment started in October 2013 and ceased in March
2015 due to discontinuation in the funding for the laboratory-based
objectives, whereas funding for the clinical objectives was retained
to complete follow-up for participants who had enrolled prior to
this date.
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2.2 Cytogenetic risk factors
Cytogenetic risk for AML was assigned according to current NCCN
guidelines [4], with the addition of results from molecular testing.
Specifically, all participating institutions had adopted routine testing
for mutations of FLT3 and NPM1 for intermediate-risk AML, and ckit
for low-risk AML. Molecular testing was only undertaken if individu-
als were candidates for induction/CR1 consolidation treatment, that
is, without significant age or comorbidities to preclude treatment with
alloSCT. If molecular testing results for FLT3 or NPM1 for interme-
diate risk or ckit mutations for core binding factor t(8;21) or inv[16]
AML were unavailable, an unconfirmed risk group status was assigned
and included in the regression analysis as a dummy variable. All
MDS-related cytogenetic changes according to theWHO 2008 classi-
fication schemewere considered to be adverse-risk AML.
2.3 Questionnaires
Following REB approval at each of the six study centers, study coor-
dinators trained in administering the questionnaires conducted inter-
views in person or over the telephone, at each of the time points.
The questionnaires were translated into Canadian-French for partic-
ipants in the province of Quebec. Sociodemographic characteristics,
treatments, outcomes, and reasons for missing data were reported on
case report forms at each of the subsequent time points and returned
to a central database. The questionnaire package included the Euro-
QoL 5-Dimension, 3-Level (EQ-5D-3L) to measure QoL according to
preference-weighted health utility and Functional Assessment of Can-
cer Therapy-Leukemia (FACT-LEU) and personal financial impact ques-
tionnaires. Clinicians provided subjective measures of health status
at each time point with measures of Karnofsky Performance Scores
along with hospital days, survival, and remission status. Results from
the EQ-5D-3L were scored according to preference weights specific
forCanada, to generateCanadianpreference-based indexutility values
[18]. Individual FACT-LEUscoreswere calculatedusingdirections from
the questionnaire provider [19]. The percentage of individual income
devoted to healthcare expenditures was determined by dividing the
sum of each participant’s self-reported expenses (specifically related
to treatment), by their monthly income. Both individual and household
income data were collected and the self-reported income measures
were adjusted to account for income sharing within a household. The
method for determining travel expenses, loss of productivity, and care-
giver impacts is provided in full detail in the Supporting Information.
2.4 Instrument validity and reliability
The validity of the EQ-5D-3L and FACT-LEU was assessed for all par-
ticipants, at each time point, through intra-instrument item correla-
tions and inter-instrument total score correlations. The reliability of
the FACT-LEUwas evaluated with the coefficient for Cronbach’s alpha
and the corrected item total correlation scores for both instruments
were calculated, at each time point. Correlation with EQ-5D-3L index
scores and the visual analogue scale (VAS) measured the relationship
of the index score to an individual’s own perception of QoL.
2.5 Endpoints and statistics
Overall survivalwasdefinedas the time fromenrollment in the study to
either deathor 24months of follow-up,whichever occurred first. Event
rateswere the ratio for the number of events to the person years at risk
for the event. The median overall survival of the cohort was estimated
using Kaplan Meir life tables and log rank equality of survivor func-
tions. Variables from established prognostic risk models (ie, age > 60,
platelets, transfusion dependence, mutational status, cytogenetic risk,
and missing cytogenetic results, for AML and IPSS-R parameters for
MDS) were included a priori. All other study variables with P-values
below .15 in a univariable analysis were included in the Cox regres-
sionandexcludedbybackward selection if their exclusion improved the
Akaike information criteria score for themodel. The coding of the vari-
ables and their selection for inclusion in themodelwere further refined
to minimize any collinearity in the models. A complete list of all of the
variables tested individually may be found in the Supporting Informa-
tion. The proportional hazards assumptionwas tested in all models and
a decision was made to adjust, stratify the model, or separately model
effects for any variables that showed time-dependent characteristics.
We used the least absolute shrinkage and selection operator (Lasso)
method to enhance the accuracy and interpretation of the results from
the Cox model [24]. The Lasso method allows all variables at multiple
timepoints to compete simultaneously to add information to themodel
and selects the most competitive variables for inclusion. Postselection
inference methods were used to compute valid P-values for the Lasso
model [25]. A bootstrapped sensitivity analyses was undertaken with
1000 resamples for all models and the Lasso results.
2.6 Multistate modeling of QoL and survival
outcomes
Multistate modeling was applied to the cohort data to simulta-
neously analyze QoL and survival outcomes. The method involves
defining a set of health states that the cohort may experience and
calculating the probability of transitions between them [20]. We dis-
tinguished health states with observed or anticipated differences in
mean QoL scores, mortality, relapse rates, and/or healthcare costs.
The QoL data and transition probabilities (ie, the probability of mov-
ing between health states over a defined period of time) were calcu-
lated for each of the health states identified. The transition process
following the initial baseline diagnosis and QoL data were modeled
instantaneously and all other transitions were modeled with Weibull
distributions, annually using a semi-Markov process starting from
the date of diagnosis or to either death, relapse, or follow-up. Any
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post-remission relapse/transformation was modeled from the date of
relapse or transformation to death or follow-up.
For each health state identified, the mean EQ-5D-3L index and
FACT-LEU scores were calculated. Any missing QoL data were
accounted for by imputingmissing values on health states with at least
60% of the complete data. Use of an imputed dataset is critical to anal-
yses of patient-reported outcomes in this disease area to adequately
represent missing date due to adverse health status. The reason for
missing data was recorded on the case report form and analyzed for
eachparticipant and timepoint. If the reasonwas related topoorhealth
status (ie, not random), the imputed data were generated from the
meanof the lowest quintile of the complete dataset, for each timepoint
(T0-T5). If the cause for the missing data was random, an imputation
model was developed for each time point, using baseline and time-
dependent covariates to generate the missing values (see Supporting
Information).
2.7 Personal financial impacts
Mann-Whitney rank sum tests were used to test mean differences in
out-of-pocket expenditures and productivity income losses due to time
off from paid work and QoL differences related to the health states
modeled for this cohort.We used Chi-squared or Fishers exact tests to
distinguish frequencies of catastrophic healthcare spending, adverse
impacts on caregiver productivity, and characteristics of nonrespond-
ing participants.
3 RESULTS
The study enrolled 188 potential participants prior to confirmation
of an AML or MDS diagnosis. Diagnostic biopsies confirmed that 41
did not have AML or MDS, and nine either did not wish to provide
consent or died prior to the second phase of enrollment. There were
138 participants enrolled and the cohort had a mean survival time of
463 days (95% CI, 353-724). Of these, 51 individuals survived the 24-
month duration of follow-up; 32 of the long-term survivors had AML
and 19 had MDS (Figure 1). The baseline demographic characteris-
tics suggest adequate representation of individuals with lower income
(38%) and other demographic characteristics (Table 1). The EQ-5D-3L
VAS scores were the least correlated with age of all the of the QoL
measures and therefore were selected for inclusion in multivariable
Cox regression models (Table 2). Two models, using baseline (T0) and
month three (T1) EQ-5D-3L VAS scores, showed that the inclusion of
this variable, and an SES indicator (high-school education or higher),
improved the accuracy of prognostic information in the model, after
adjustment for risk factors with known prognostic value, such as dis-
ease type, baseline platelet counts, and age above 60. The accuracy of
bothbaseline andmonth threemodels improvedwhen the resultswere
stratified for males and females; however, the results from the mod-
els did not change when the sex-stratified models were analyzed sep-
arately, with this sample size. When all variables were allowed to
F IGURE 1 Enrolment and attrition of eligible participants over
the 24-month term of follow-up
compete for inclusion in the Lasso model, the QoL and SES variables
were always selected along with the established risk factors used for
the NCCN guidelines and IPSS. The Lasso model selected the month 3
EQ-5D-3L VAS scores as the most important predictor (P = .03; 92%
successful selection) (Figure 2).
The correlation coefficients for the QoL instruments were close to
1 when drawing comparison between the FACT-LEU and EQ-5D-3L
(ranging between 0.68 and 0.87), suggesting good convergent validity
between the twoQoL instruments. Correlation of the EQ-5D-3L index
score with the VAS, however, indicated the instrument had poor con-
struct validity (alpha ranged between 0.40 and 0.68) across all time
points. The corrected item total correlations (CITC) indicated only fair
reliability for both instruments, with some CITC scores falling below
the commonly referenced thresholds for reliability of 0.2; specifically,
theCITC score for the anxiety and depression itemon the EQ-5D-3L at
month 6 was 0.16 and the social and family well-being subscale of the
FACT-LEU at baseline was 0.17.
The multistate modeling defined 10 finite health states for this
cohort (Figure 3 and Table 3). MeanQoL scores were found to improve
over time for patients with AML who had a complete remission and
remained stable over time for patients who received standard care
for MDS. The least preferred health states were those with the
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TABLE 1 Baseline characteristics and unadjusted hazards for overall survival
Unadjusted hazard ratios
Baseline frequency
(%)N= 138
a
HR (95%CI) P-value
Median age (IQR, Range) 64 (53-73, 18-91) 1.02 (1.00-1.03) .01
<40 years 20 (14.5%) 1 (reference)
40-49 years 10 (7.3%) 1.40 (0.45-4.43) .56
50-59 years 24 (17.4%) 1.43 (0.56-3.63) .45
60-69 years 38 (28.0%) 2.17 (0.94-4.99) .07
70-79 years 33 (23.9%) 2.76 (1.18-6.46) .02
≥80 years 13 (9.4%) 1.61 (0.54-4.82) .39
Sex (%male) 71 (51%) 1.08 (0.69-1.67) .32
Ethnicity
White 107 (78%) 1.33 (0.66-2.67) .43
Non-White 20 (14%)
Missing response 11 (8%)
Marriage and cohabitation status
Married or common-law 88 (64%) 0.93 (0.57-1.49) .75
Living alone 30 (22%) 1.24 (0.74-2.07) .43
Net incomemedian (IQR)
b
$27 500 ($15 000-$42 500) 1.00 (1.00-1.00) .07
Income levels
<$20 000/year 32 (37.7%) 1 (reference)
$20 000-49 999 38 (44.7%) 0.62 (0.31-1.24) .18
≥$50 000/year 15 (17.7%) 1.47 (0.68-3.13) .32
Missing response 53 (38%)
Income< $20 000/year 1.88 (1.02-3.45) .04
Formal Education (in seven levels)
Less than grade 8 (level 1) 10 (7.8%) 1 (reference)
Grades 9-11 38 (29.5%) 0.26 (0.12-0.58) .00
High school diploma 18 (14.0%) 0.46 (0.20-1.08) .07
Some college 22 (17.1%) 0.19 (0.08-0.49) .00
Some university 25 (19.4%) 0.35 (0.15-0.79) .01
Bachelor’s degree 7 (5.4%) 0.36 (0.15-0.91) .08
Graduate degree 9 (7.0%) 0.39 (0.15-0.91) .07
Missing response 9 (7.0%)
Disease type
AML (vsMDS) 109 (79.0%) 1.70 (0.94-3.10) .08
De novo AML
c
(vs all others) 92 (68.2%) 1.08 (0.67-1.74) .74
AML risk group
d
Favorable 17 (12.3%) 1 (reference) .00
Intermediate 19 (13.8%) 5.43 (1.53-19.32) .01
Adverse 48 (34.8%) 7.19 (2.20-23.52) .00
Missing cytogenetic results 6 (4.4%) 32.90 (6.45-170.22) .00
Low and intermediate IPSS-R 20 (14.5%) 2.69 (0.71-10.15) .14
High and very high IPSS-R 9 (6.5%) 4.37 (1.04-18.34) .04
Abbreviations: AML, acute myeloid leukemia; CR1, first complete remission; IPSS-R, International Prognostic Scoring System for MDS, revised; IQR,
interquartile range; SCT, stem cell transplant.
aThe frequency of missing responses are reported if the total is greater than 5%.
bSelf-reported baseline net household or individual income, adjusted for marital status.
cNewly diagnosed AML, without known history ofMDS.
dAML risk group according to 2017National Comprehensive Cancer Network guidelines.
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TABLE 2 Baseline and threemonth adjusted survival models
Variable Baselinemodel (T0) Month threemodel (T1)
HR (95%CI) P-value HR (95%CI) P-value
Disease type
a
MDS 1 (reference) 1 (reference)
Low-risk AML 0.71 (0.19-2.66) .61 0.57 (0.06-5.51) .62
Intermediate-risk AML 2.45 (1.17-5.10) .02 3.43 (1.24-9.48) .02
High-risk AML 4.37 (2.07-9.25) <.01 5.07 (1.61-15.99) <.01
AMLwithmissing cytogenetics 18.71 (3.31-105.83) <.01 – –
Age above 60 2.66 (1.49-4.74) <.01 1.31 (0.56-303) .53
Baseline platelets
b
<50× 109/L 1 (reference) 1 (reference)
50-120× 109/L 0.94 (0.54-1.66) .84 0.99 (0.45-2.16) .98
>120× 109/L 1.96 (1.04-3.68) .04 2.00 (0.79-5.02) .14
First complete remission – – 0.40 (0.18-0.87) .02
Some high school or higher 0.30 (0.14-0.66) <.01 0.31 (0.12-0.82) .02
EQ-5D-VAS
b
0.98 (0.97-0.99) <.01 0.97 (0.95-0.99) <.01
Sample size (n respondents)
c
126 79
aIntegrated cytogenetic and genomic risk according to 2017National Comprehensive Cancer Network guidelines for transplant-eligible patients with AML
bVisual analogue scale measures from the Euroqol five-dimension, three-level questionnaire at either baseline (T0) or month three (T1)
cThemodel is stratified bymale and female sex
F IGURE 2 Variable importance and selection by the Lassomodel. Variable importance is the proportion of bootstrap resamples in which the
variable was selected
highest mortality rates, including newly diagnosed, relapsed, refrac-
tory, or transformed AML. The parameters for the parametric
survival models used to calculate transition probabilities are provided
in the Supporting Information. Questionnaire response rates from par-
ticipants were highest for the first three study time points (greater
than 65%) and fell as low as 47% for T4 due to inconsistency in study
staffing, when the funding of the study was under review. Response
rates returned to 65% after the study review period for T5. Themajor-
ity of missing questionnaire data were missing at random due to dis-
continuity of staffing (see Supporting Information). A comparison of
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F IGURE 3 Health states definitions
the characteristics of participants with missing responses showed that
missing data were from younger participants and from one study
center with the most participants and discontinuous staffing (P < .05).
AMLpatientswho had remissions longer than 6months and thosewith
MDSweremore likely to respondwith scores of perfect health, indicat-
ing a ceiling effect for the instrument and potential aggreability bias for
people withmore desirable outcomes.
When compared to MDS, the mean out-of-pocket expenses (ie,
costs for travel to clinics, accommodations, and uninsured prescrip-
tion drugs) were higher for patients with AML at month three ($559
vs $239; P= .05) and high medical costs may persist over longer terms
of follow-up; month six mean out-of-pocket expenses were $334 ver-
sus $129, P = .06. Nearly two thirds (67%) of all study participants
reported out-of-pocket medical expenses that totaled more than 5%
of their monthly income. Patients with AML who were in remission
also reported greater productivity income losses at both T1 and T2
time points compared to all other patients. At T1 (3 months), patients
with AML who had productivity income loss paid an uninsured aver-
age of $1786 (95% CI, $1293-$2278) in lost income per month com-
pared to $708 (95% CI, $164-$1353) reported by patients with MDS
(P< .05). ComparedwithparticipantswithMDS, participantswithAML
were younger (mean age 58 vs 69 for MDS; P < .05) and more likely
to be employed in either full or part-time work at baseline (52% of all
participants with AML vs 24% of all participants with MDS, P < .05).
Fewer than 10% of all patients who had alloSCT—and were working at
baseline—returned to workwithin a year. In addition, participants with
AML reported greater caregiver productivity losses such as foregone
employment, use of vacation time, or unpaid leave for at least 6months
compared with caregiver impacts for participants with MDS (65% vs
35% at 6 months; P < .05). Mean hospital days over the first 6 months
of treatment were similar for patients with AML and MDS (48 vs
45 days, respectively; P= .70).
4 DISCUSSION
The results from this study suggest that data on patient-reported QoL
and SES can improve the accuracy of risk models and that scores from
the EQ-5D-3L’s visual analogue scale are the most important predic-
tor to include in post-remission survivalmodels. TheVAS is a subjective
measure reflecting a patient’s own concept ofQoL.Our results suggest
that including the VAS or other patient-reported QoL measures can
improve the accuracy how risk is communicated to patients. The novel
finding that theVASwas themost important predictor also raises ques-
tions about howwell theQoL instruments represent outcomes that are
meaningful to patients.
The instruments used to measure QoL in this study were found
to be only moderately reliable and the EQ-5D-3L notably suffered
ceiling effects that often indicates agreeability bias. The EQ-5D-5L
has been developed since this analysis in an effort to mitigate ceiling
effects in other disease areas. Our findings concur with the literature
suggesting that measuring QoL for AML may require more specific
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instruments due to the severity of the disease and the wide range of
treatments and outcomes implied over time [21-23]. Our results are
consistent with results from elderly patients with AML that do not
report differences in QoL between intensive and nonintensive treat-
ments with the FACT-LEU [24]. A better understanding of the associa-
tion between QoL and prognosis could improve concerns over trans-
parency and poor communication flow between patients with AML
and their attending clinicians [25]. The income and productivity losses
we observe agree with the literature on adverse patient-reported out-
comes for AML in other countries and studies suggesting the need for
financial support for people receiving treatment for AML [26-28].
Our study is limited by missing responses arising mostly from dis-
continuity in study staffing. Despite this limitation, sufficient datawere
captured to show socioeconomic and financial disparity in this cohort.
This is a novel accomplishment for this disease area, highlightingpoten-
tial for including patient-reported outcomes in future studies. The
response rates were similar to those reported from other studies of
these diseases with more frequent missing values for individuals with
poorer survival outcomes such as AML patients who did not receive
induction therapy, or whose therapy did not result in CR1. There were,
however, lower response rates for income and race/ethnicity questions
than other baseline demographic reply items.Our results are therefore
conservative in estimating the extent of disparity for AML patients and
overrepresent outcomes for healthy individuals of higher SES.
The potential for QoL and SES variables to improve the accuracy
of survival models warrants further attention. QoL outcomemeasures
should be routinely obtained in clinical trials and the question on how
meaningful those outcomes are needs to be robustly explored. Collect-
ing information on SES from patients in research studies may improve
population outcomes with information on disparity or potential gaps
in unemployment insurance coverage. In Canada, any out-of-pocket
expenditure greater than 5% of a person’s net income is considered
catastrophic and requires policy to protect those affected [29] The
information from this study therefore suggests that Canadians with
AML facemore financial disparity than patients with similar conditions
that requires policy attention.
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